

List of Cancer Drugs (the first batch)

I .Cancer drugs			
NO.	Generic name of active ingredient	Approved dosage by CFDA	HS code
1	Anastrozole	Tablet	30049090
2	Cytarabine	Injection	30021900
3	Axitinib	Tablet	30049090
4	Azacitidine	Injection	30049090
5	Oxaliplatin	Injection	30049090
6	Oteracil/Gimeracil/Tegafur	Capsule, Tablet	30049090
7	Busulfan	Tablet, Injection	30049090
8	Chlorambucil	Tablet	30049090
9	Bicalutamide	Tablet, Capsule	30049090
10	Epirubicin	Injection	30042090
11	Abiraterone Acetate	Tablet	30043900
12	Octreotide acetate	Injection	30043900
13	Goserelin acetate	Implant	30043200
14	Leuprorelin acetate	Injection	30043900
15	Triptorelin Acetate	Injection	30043200
16	Dacarbazine	Injection	30049090
17	Dasatinib	Tablet	30049090
18	Decitabine	Injection	30049090
19	Docetaxel	Injection	30049090
20	Fluorouracil	Injection,Tablet,Oral Emulsion,Emulsifiable paste,Implant,Oral Solution	30041090
21	Flutamide	Tablet, Capsule	30049090
22	Fulvestrant	Injection	30043200
23	Formestane	Injection	30043900
24	Fotemustine	Injection	30049090
25	Tamoxifen citrate	Tablet,Oral Solution	30049090
26	Toremifene citrate	Tablet	30049090
27	Cytosan	Injection,Tablet	30049090
28	Gefitinib	Tablet	30049090
29	Methotrexate	Injection	30049090
30	lapatinib ditosylate monohydrate	Tablet	30049090
31	Sorafenib tosylate	Tablet	30049090

32	Apatinib Mesylate	Tablet	30049090
33	Osimertinib Mesylate	Tablet	30049090
34	Imatinib Mesylate	Capsule,Tablet	30049090
35	Vinorelbine Tartrate	Capsule, Injection	30044900
36	Carboplatin	Injection	30049090
37	Carmofur	Tablet	30049090
38	Capecitabine	Tablet	30049090
39	Cladribine	Injection	30049090
40	Crizotinib	Capsule	30049090
41	lenalidomide	Capsule	30049090
42	Letrozole	Tablet	30049090
43	Raltitrexed	Injection	30049090
44	Estradiol phosphate	Capsule	30043900
45	Fludarabine Phosphate	Tablet, Injection	30049090
46	Ruxolitinib Phosphate	Tablet	30049090
47	Etoposide phosphate	Injection	30049090
48	Vindesine sulfate	Injection	30044900
49	Vincristine Sulphate	Injection	30044900
50	Lobaplatin	Injection	30049090
51	Afatinib dimaleate	Tablet	30049090
52	Melphalan	Tablet	30049090
53	Asparaginase	Injection	30049090
54	Nedaplatin	Injection	30049090
55	Nilotinib	Capsule	30049090
56	Pemetrexed disodium	Injection	30049090
57	Pegaspargase	Injection	30049090
58	Pazopanib	Tablet	30049090
59	Bortezomib	Injection	30049090
60	Sunitinib Malate	Capsule	30049090
61	Hydroxycamptothecin	Injection	30044900
62	Mercaptopurine	Tablet	30049090
63	Doxifluridine	Tablet, Capsule, Dispersible Tablet	30049090
64	Regorafenib	Tablet	30049090
65	Triptorelin pamoate	Injection	30043900
66	Cisplatin	Injection	30049090
67	Mitomycin	Injection	30042090
68	Tegafur	Tablet, Injection	30049090
69	Temozolomide	Capsule	30049090
70	Teniposide	Injection	30049090
71	Vemurafenib	Tablet	30049090
72	Chidamide	Tablet	30049090
73	Calcium Folate	Injection	30049090

74	Sodium folinate	Injection	30049090
75	Cytarabine hydrochloride	Injection	30049090
76	Icotinib hydrochloride	Tablet	30049090
77	Pirarubicin hydrochloride	Injection	30049090
78	Epirubicin hydrochloride	Injection	30049090
79	Bleomycin hydrochloride	Injection	30042090
80	Chlormethine hydrochloride	Injection	30049090
81	Doxorubicin hydrochloride	Injection	30042090
82	Erlotinib hydrochloride	Tablet	30049090
83	Gemcitabine hydrochloride	Injection	30049090
84	Nimustine hydrochloride	Injection	30049090
85	Pingyang mycin hydrochloride	Injection	30042090
86	Daunorubicin hydrochloride	Injection	30042090
87	Topotecan Hydrochloride	Injection	30044900
88	Idarubicin hydrochloride	Capsule, Injection	30042090
89	Irinotecan Hydrochloride	Injection	30049090
90	Ibrutinib	Capsule	30049090
91	Etoposide	Capsule, Injection	30049090
92	Everolimus	Tablet	30049090
93	Exemestane	Tablet	30043200
94	Ifosfamide	Injection	30049090
95	Vinorelbine Bitartrate	Injection	30044900
96	Paclitaxel	Injection	30049090
97	Calcium levofolinate	Injection	30049090
98	Uracil/ Tegafur	Tablet, Capsule	30049090
99	Bevacizumab for Injection	Injection	30021500
100	Rituximab for Injection	Injection	30021500
101	Cetuximab for Injection	Injection	30021200
102	Trastuzumab for Injection	Injection	30021500
103	Nimotuzumab for Injection	Injection	30021500

II.Active Pharmaceutical Ingredient		
NO.	Generic name of active ingredient	HS code
1	Anastrozole	29339900
2	Oxaliplatin	28439000
3	Potassium oxonate	29336990
4	Busulfan	29053990
5	Bicalutamide	29309090
6	Pirarubicin	29419090
7	Triptorelin Acetate	29371900

8	Dasatinib	29341090
9	Decitabine	29349990
10	Docetaxel	29329990
11	Floxuridine	29349990
12	Flutamide	29242990
13	Formestane	29372319
14	Cytosan	29349990
15	Gefitinib	29349990
16	Gimeracil	29333990
17	Apatinib Mesylate	29333990
18	Imatinib Mesylate	29335990
19	Vinorelbine Tartrate	29397990
20	Carboplatin	28439000
21	Capecitabine	29349990
22	lenalidomide	29337900
23	Letrozole	29339900
24	Raltitrexed	29349990
25	Fludarabine Phosphate	29349990
26	Vincristine Sulphate	29397990
27	Azathioprine	29335990
28	Asparaginase	35079090
29	Nedaplatin	28439000
30	Pemetrexed disodium	29335990
31	Bortezomib	29339900
32	Cisplatin	28439000
33	Mitomycin	29419090
34	Tegafur	29349990
35	Temozolomide	29339900
36	Chidamide	29333990
37	Cytarabine hydrochloride	29349990
38	Icotinib hydrochloride	29349990
39	Epirubicin hydrochloride	29419090
40	Doxorubicin hydrochloride	29419090
41	Gemcitabine hydrochloride	29349990
42	Mitoxantrone hydrochloride	29225090
43	Pingyang mycin hydrochloride	29419090
44	Daunorubicin hydrochloride	29419090
45	Topotecan hydrochloride	29397990
46	Idarubicin hydrochloride	29419090
47	Irinotecan hydrochloride	29397990
48	Exemestane	29372900
49	Ifosfamide	29349990

50	Paclitaxel	29329990
51	Calcium levofolinate	29335990

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. Please see [About Deloitte](#) for a more detailed description of DTTL and its member firms.

Privacy

Thank you for your interest in Deloitte China services. Deloitte China would like to continue to use your personal information (in particular name and contact details) for the purpose of sending you marketing and regulatory updates, invitations to seminars and other events organized, sponsored or promoted by Deloitte China. If you do not wish to receive further communications from Deloitte China, please send a return email to the sender with the word “Unsubscribe” in the subject line.

If you would like to update your personal information, please click [here](#).

Deloitte China refers to Deloitte Touche Tohmatsu in Hong Kong, Deloitte Touche Tohmatsu in Macau, Deloitte Touche Tohmatsu Certified Public Accountants LLP in the Chinese Mainland and their respective affiliates practising in Hong Kong, Macau and the Chinese Mainland.

This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the “Deloitte Network”) is by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this communication.

© 2018 Deloitte Touche Tohmatsu in Hong Kong, Deloitte Touche Tohmatsu in Macau, and Deloitte Touche Tohmatsu Certified Public Accountants LLP in the Chinese Mainland. All rights reserved.